CY1117792T1 - Ανταγωνιστες toy trpv4 - Google Patents

Ανταγωνιστες toy trpv4

Info

Publication number
CY1117792T1
CY1117792T1 CY20161100556T CY161100556T CY1117792T1 CY 1117792 T1 CY1117792 T1 CY 1117792T1 CY 20161100556 T CY20161100556 T CY 20161100556T CY 161100556 T CY161100556 T CY 161100556T CY 1117792 T1 CY1117792 T1 CY 1117792T1
Authority
CY
Cyprus
Prior art keywords
trpv4
competitors
toy
compounds
relates
Prior art date
Application number
CY20161100556T
Other languages
English (en)
Inventor
Carl Brooks
Mui Cheung
Hilary Schenck Eidam
Krista B Goodman
Marlys Hammond
Mark A Hilfiker
Tram H Hoang
Jaclyn R Patterson
Patrick Stoy
Guosen Ye
Original Assignee
Glaxosmithkline Intellectual Property (No. 2) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47558389&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117792(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Intellectual Property (No. 2) Limited filed Critical Glaxosmithkline Intellectual Property (No. 2) Limited
Publication of CY1117792T1 publication Critical patent/CY1117792T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Abstract

Η παρούσα εφεύρεση σχετίζεται με σπειροκαρβαμικές ενώσεις του Χημικού Τύπου (I) στον οποίον τα R1, (R2)Y, R3, R4, Χ και Α έχουν τις έννοιες που αποδίδονται στην προδιαγραφή. Η εφεύρεση παρέχει περαιτέρω φαρμακευτικές συνθέσεις περιέχοντας τις ενώσεις ή τα φαρμακευτικώς αποδεκτά άλατα εξ' αυτών και σχετίζεται με την χρήση αυτών των ενώσεων ως ανταγωνιστές του TRPV4 στην αγωγή ή πρόληψη καταστάσεων που συσχετίζονται με ανισοζύγιο του TRPV4.
CY20161100556T 2011-06-17 2016-06-21 Ανταγωνιστες toy trpv4 CY1117792T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498110P 2011-06-17 2011-06-17
PCT/US2012/042622 WO2013012500A1 (en) 2011-06-17 2012-06-15 Trpv4 antagonists

Publications (1)

Publication Number Publication Date
CY1117792T1 true CY1117792T1 (el) 2017-05-17

Family

ID=47558389

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100556T CY1117792T1 (el) 2011-06-17 2016-06-21 Ανταγωνιστες toy trpv4

Country Status (38)

Country Link
US (1) US9187464B2 (el)
EP (2) EP3121177B1 (el)
JP (1) JP5969017B2 (el)
KR (1) KR101870003B1 (el)
CN (1) CN103732583B (el)
AR (1) AR086958A1 (el)
AU (1) AU2012284540B2 (el)
BR (1) BR112013032391B1 (el)
CA (1) CA2839743C (el)
CL (1) CL2013003602A1 (el)
CO (1) CO6821953A2 (el)
CR (1) CR20130671A (el)
CY (1) CY1117792T1 (el)
DK (1) DK2721016T3 (el)
DO (1) DOP2013000307A (el)
EA (1) EA023616B1 (el)
ES (2) ES2569193T3 (el)
HK (1) HK1195068A1 (el)
HR (1) HRP20160539T1 (el)
HU (1) HUE029594T2 (el)
IL (1) IL229872A (el)
JO (1) JO3154B1 (el)
MA (1) MA35184B1 (el)
ME (1) ME02416B (el)
MX (1) MX337440B (el)
MY (1) MY173521A (el)
PE (1) PE20141943A1 (el)
PL (1) PL2721016T3 (el)
PT (1) PT2721016E (el)
RS (1) RS54858B1 (el)
SG (1) SG195106A1 (el)
SI (1) SI2721016T1 (el)
SM (1) SMT201600150B (el)
TW (1) TWI538912B (el)
UA (1) UA113963C2 (el)
UY (1) UY34138A (el)
WO (1) WO2013012500A1 (el)
ZA (1) ZA201308816B (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2720546B1 (en) 2011-06-17 2016-04-06 Glaxosmithkline Intellectual Property (No. 2) Limited Spiro-cyclic trpv4 antagonists
WO2012174340A1 (en) 2011-06-17 2012-12-20 Glaxosmithkline Llc Trpv4 antagonists
EP2832731A4 (en) 2012-03-27 2015-08-19 Shionogi & Co AROMATIC HETEROCYCLIC CHAIN 5-CORE DERIVED DERIVATIVE HAVING TRPV4 INHIBITORY ACTIVITY
JPWO2015046193A1 (ja) 2013-09-25 2017-03-09 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
US10968209B2 (en) 2016-05-19 2021-04-06 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonist
EP3458451B1 (en) * 2016-05-19 2020-06-03 Glaxosmithkline Intellectual Property (No. 2) Limited Trpv4 antagonist
WO2018185701A1 (en) 2017-04-06 2018-10-11 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists as antitussive agents
EA202091101A1 (ru) * 2017-11-01 2020-08-06 Бристол-Маерс Сквибб Компани Спироциклические соединения в качестве модуляторов фарнезоидного x-рецептора
WO2021170811A1 (en) 2020-02-27 2021-09-02 Glaxosmithkline Intellectual Property (No.2) Limited Method of treating eye disease using trpv4 antagonists
CA3180132A1 (en) 2020-04-30 2021-10-30 Raqualia Pharma Inc. Pyrimidin-4(3h)-one derivatives as trpv4 antagonists
CN111704613B (zh) * 2020-06-23 2021-07-06 中国人民解放军军事科学院军事医学研究院 咪唑类衍生物及其作为trpv4抑制剂的用途
MX2023000610A (es) 2020-07-16 2023-02-13 Raqualia Pharma Inc Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.
WO2024011214A1 (en) 2022-07-08 2024-01-11 Actio Biosciences, Inc. Therapeutic compounds and methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3851199A (en) * 1998-05-26 1999-12-13 Chugai Seiyaku Kabushiki Kaisha Heterocyclic indole derivatives and mono- or diazaindole derivatives
AU2004257289A1 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
WO2007059608A1 (en) * 2005-11-23 2007-05-31 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
WO2007067756A2 (en) 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
CA2634152A1 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
TW200819457A (en) * 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
TW200900060A (en) * 2007-02-01 2009-01-01 Glaxo Group Ltd Chemical compounds
GB0707934D0 (en) * 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
WO2009023539A2 (en) * 2007-08-09 2009-02-19 Abbott Laboratories Tetrahydropyridine carboxamide derivatives as trpvl antagonists
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
ES2453075T3 (es) 2008-07-25 2014-04-03 Glaxosmithkline Llc Antagonistas de TRPV4
JP2012006837A (ja) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd ２−インドールアクリルアミド類縁体
US8742110B2 (en) * 2010-08-18 2014-06-03 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
WO2012174340A1 (en) * 2011-06-17 2012-12-20 Glaxosmithkline Llc Trpv4 antagonists
EP2720546B1 (en) * 2011-06-17 2016-04-06 Glaxosmithkline Intellectual Property (No. 2) Limited Spiro-cyclic trpv4 antagonists

Also Published As

Publication number Publication date
EP3121177A1 (en) 2017-01-25
ES2688733T3 (es) 2018-11-06
AU2012284540B2 (en) 2014-08-28
CA2839743A1 (en) 2013-01-24
DOP2013000307A (es) 2014-06-01
PL2721016T3 (pl) 2017-01-31
SG195106A1 (en) 2013-12-30
EP2721016B1 (en) 2016-04-06
MX2013014898A (es) 2014-03-21
AU2012284540A1 (en) 2013-04-04
CO6821953A2 (es) 2013-12-31
RS54858B1 (sr) 2016-10-31
MY173521A (en) 2020-01-30
TWI538912B (zh) 2016-06-21
US20140121206A1 (en) 2014-05-01
SMT201600150B (it) 2016-07-01
EA023616B1 (ru) 2016-06-30
PE20141943A1 (es) 2014-12-28
CN103732583A (zh) 2014-04-16
BR112013032391A2 (pt) 2016-08-16
UA113963C2 (xx) 2017-04-10
MX337440B (es) 2016-03-03
TW201313705A (zh) 2013-04-01
EA201490037A1 (ru) 2015-12-30
ZA201308816B (en) 2015-02-25
KR20140041733A (ko) 2014-04-04
BR112013032391B1 (pt) 2020-11-24
ME02416B (me) 2016-09-20
AR086958A1 (es) 2014-02-05
JP5969017B2 (ja) 2016-08-10
IL229872A (en) 2017-03-30
EP3121177B1 (en) 2018-08-01
MA35184B1 (fr) 2014-06-02
CN103732583B (zh) 2015-12-23
NZ618221A (en) 2015-02-27
DK2721016T3 (en) 2016-06-06
HRP20160539T1 (hr) 2016-06-17
US9187464B2 (en) 2015-11-17
EP2721016A1 (en) 2014-04-23
SI2721016T1 (sl) 2016-06-30
EP2721016A4 (en) 2014-10-08
HUE029594T2 (en) 2017-03-28
JO3154B1 (ar) 2017-09-20
KR101870003B1 (ko) 2018-06-22
WO2013012500A1 (en) 2013-01-24
PT2721016E (pt) 2016-06-06
CA2839743C (en) 2017-03-28
CR20130671A (es) 2014-02-04
UY34138A (es) 2013-01-03
ES2569193T3 (es) 2016-05-09
JP2014518214A (ja) 2014-07-28
CL2013003602A1 (es) 2014-07-04
HK1195068A1 (zh) 2014-10-31

Similar Documents

Publication Publication Date Title
CY1117792T1 (el) Ανταγωνιστες toy trpv4
CY1124117T1 (el) Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων
CY1121867T1 (el) Αναστολεις jak2 και alk2 και μεθοδοι για τη χρηση τους
CY1118735T1 (el) Παραγωγα βενζιμιδαζολο-προλινης
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
UA108640C2 (uk) Похідні n-(імідазопіримідин-7-іл)гетероариламідів та їх застосування як інгібіторів pde10a
EA201070597A1 (ru) Антибактериальные аналоги аминогликозида
MX348422B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
UY35182A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[ 3,4-d][1,3]TIAZIN-2-AMINA? .
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
EA201792071A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
GB201209587D0 (en) Therapeutic compounds
BR112012030482A2 (pt) tratamento de diabetes tipo 2
MY165918A (en) Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
TR201902057T4 (tr) Tetrasiklin bileşikleri.
MX2012009224A (es) Compuestos en calidad de antagonistas de bradiquinina-b1.
CY1116012T1 (el) Ενωσεις πυραζολιου ως ανταγωνιστες toy crth2
CO6382113A2 (es) Compuestos quimicos
BR112012013319A8 (pt) derivados espiro azacíclicos